Prescribing information

 

Prescribing information

       

Cosentyx is indicated for the treatment of: moderate to severe plaque psoriasis in adults who are candidates for systemic therapy; active psoriatic arthritis in adult patients, alone or in combination with MTX, when the response to previous DMARD therapy has been inadequate; active ankylosing spondylitis in adults who have responded inadequately to conventional therapy; active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated CRP and/or MRI evidence in adults who have responded inadequately to NSAIDs.

Discover how we are working to reimagine PsA and axSpA management

We appreciate the challenges you face in today’s clinic environment – that’s why we’ve created this online events resource where you can connect with the latest evidence and opinions in the management of PsA and axSpA in your own time.

 

BSR 2021

Preview of webinar video under the heading 'BSR 2021' entitled: 'Evolving rheumatology services to support PsA patients in a new world'

Evolving rheumatology services to support PsA patients in a new world

If you missed us at BSR 2021, you can watch the session here on demand. You will hear our multidisciplinary panel of experts, Dr Antoni Chan, Dr Kirsten MacKay, Julie Begum, and Anusha Patel discuss the PsA patient journey and the impact of COVID-19 on rheumatology practices.

Find out more

 

New for 2021

Joint clinics: combining dermatology and rheumatology care within your Trust

Listen to Professor Miriam Wittmann and Dr Helena Marzo-Ortega discuss the importance of joint plaque psoriasis (PsO) and psoriatic arthritis (PsA) clinics and offer perspectives on how joint dermatology-rheumatology clinics can be established within a Trust and what benefits they can offer.

Access now

 

Thumbnail image of video

Treating plaque psoriasis (PsO) and psoriatic arthritis (PsA) patients with multiple manifestations

Hear Dr Christos Kasparis and Professor Laura Coates discuss the management of PsO and PsA with multiple manifestations and offer perspectives on the importance of timely screening and treating appropriate patients early with the right biologic.

Access now

 

Preview of webinar video under the heading 'New for 2021' entitled: 'Paradigm shift: IL-17A inhibition and PsA and axaSpA'

Paradigm shift: IL-17A inhibition in PsA and axSpA (AS and nr-axSpA)

Hear UK-based rheumatology experts, Laura Coates, Paul Emery, Bruce Kirkham and Raj Sengupta, critically assess the latest clinical trial evidence for IL-17A inhibition with Cosentyx, in the management of PsA and axSpA, and how this can direct future therapy choice.

Access now (registration is required to verify your profession)

 

Best of 2020

Preview of BSR 2020 webinar recording under the heading 'Best of 2020' entitled: 'Reimagining PsA: Raising the standard of care for patients'

Reimagining PsA: Raising the standard of care for patients

As shown at EULAR and BSR, hear insights on treatment strategies for PsA from renowned, international medical experts, Laura Coates, Philip Conaghan, Désirée van der Heijde, Peter Nash and Grace Wright, and discover the latest head-to-head trial data.

Access now (registration is required to verify your profession)

 

 

Arrow with the text Why target IL-17A? Click to find out more

Arrow with the text Why Cosentyx in PsA? Click to find out more

Arrow with the text Why Cosentyx in axSpA? Click to find out more

AS, ankylosing spondylitis; axSpA, axial spondyloarthritis; BSR, British Society for Rheumatology; DMARD, disease-modifying antirheumatic drug; EULAR, European League Against Rheumatism; IL, interleukin; MRI, magnetic resonance imaging; nr-axSpA, non-radiographic axial spondyloarthritis; NSAID, non-steroidal anti-inflammatory drug; PsA, psoriatic arthritis; PsO, plaque psoriasis.

Rate this content: 
No votes yet
UK | June 2021 | 131162
×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at www.report.novartis.com
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]